Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Picard Medical, Inc. ( (PMI) ).
On December 9, 2025, Picard Medical, Inc. announced a significant milestone as a patient surpassed eight years, or 2,900 days, living with the SynCardia Total Artificial Heart, marking the longest recorded duration for an artificial heart. This achievement underscores the SynCardia heart’s durability and life-saving potential, particularly in Serbia, where the longest-supported patients are treated, highlighting the dedication of the medical teams at IVDK Dedinje Hospital. Picard Medical is leveraging this success to develop the next generation of artificial heart systems, aiming to expand access and enhance long-term support globally.
More about Picard Medical, Inc.
Picard Medical, Inc., headquartered in Tucson, Arizona, is the parent company of SynCardia Systems, LLC. It is a leader in the development, manufacturing, and commercialization of the SynCardia Total Artificial Heart, the only commercially available artificial heart technology approved by both the U.S. FDA and Health Canada. This system is designed for patients with end-stage heart failure, and over 2,100 implants have been performed in 27 countries, making it the most widely used artificial heart globally.
Average Trading Volume: 2,601,530
For a thorough assessment of PMI stock, go to TipRanks’ Stock Analysis page.